Mario Balsa, Medical Oncology resident at Institut Català d’Oncologia (ICO), shared on X about a recent paper by Joshua E. Reuss et al. published in JCO:
“ASCO 2025 guideline updates on stage IV NSCLC with driver alterations
- EGFR: Osimertinib remains top
- ALK: Alectinib or Lorlatinib. ¿Brigatinib? Twirl and exit
- KRAS G12C: Sotorasib/Adagrasib post-CT
A living document for a fast-evolving field. Lung cancer doesn’t stand still, and neither should we.”
Title: Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1
Authors: Joshua E. Reuss, Sara Kuruvilla, Nofisat Ismaila, Ibrahim Hanna Azar, Jill Feldman, Naoki Furuya, Paul Wheatley-Price, Logan Roof, Ana I. Velazquez, Yubao Wang, Natasha B. Leighl.
More posts featuring ASCO 2025.